Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Maternal and Child Health Journal
Published in: Maternal and Child Health Journal 3/2006

01-05-2006 | Original Article

Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study

Authors: Amelia M. Arria, PhD, Chris Derauf, MD, Linda L. LaGasse, PhD, Penny Grant, MD, Rizwan Shah, MD, Lynne Smith, MD, William Haning, MD, Marilyn Huestis, PhD, Arthur Strauss, MD, Sheri Della Grotta, MPH, Jing Liu, PhD, Barry Lester, PhD

Published in: Maternal and Child Health Journal | Issue 3/2006

Login to get access

Abstract

Objectives: Methamphetamine use is a continuing problem in several regions of the United States and yet few studies have focused on prenatal methamphetamine exposure. The purpose of this study was to estimate the prevalence and correlates of alcohol, tobacco, and other substance use—including methamphetamine—during pregnancy. Methods: The sample consisted of the first 1632 eligible mothers who consented to participate in a large-scale multisite study focused on prenatal methamphetamine exposure. This unselected screening sample included both users and nonusers of alcohol, tobacco, methamphetamine, and other drugs. Substance use was determined by maternal self-report and/or GC/MS confirmation of a positive meconium screen. Results: Overall, 5.2% of women used methamphetamine at some point during their pregnancy. One quarter of the sample smoked tobacco, 22.8% drank alcohol, 6.0% used marijuana, and 1.3% used barbiturates prenatally. Less than 1% of the sample used heroin, benzodiazapenes, and hallucinogens. Multivariate modeling results showed that tobacco smokers and illicit drug users were more likely to be single and less educated, have attended less than 11 prenatal visits, and utilize public financial assistance. Conclusions: This is the first large-scale investigation to report the prevalence of methamphetamine use during pregnancy in areas of the United States where methamphetamine is a notable concern. Follow-up research is ongoing to investigate the outcomes associated with prenatal methamphetamine exposure. Given that this research extends and confirms previous findings showing that high-risk groups of pregnant women can be identified on the basis of basic demographic characteristics, targeted interventions are greatly needed to reduce serious adverse outcomes associated with prenatal alcohol and tobacco use.
Literature
1.
Lester BM, Andreozzi L, Appiah L. Substance use during pregnancy: Time for policy to catch up with research. Harm Reduction J 2004;1(5):1–44.CrossRef
2.
Hanson JW, Jones KL, Smith DW. Fetal alcohol syndrome. Experience with 41 patients. JAMA 1976;235(14):1458–60.CrossRefPubMed
3.
Bauer CR. Perinatal effects of prenatal drug exposure: Neonatal aspects. Clin Perinatol 1999;26:87–106.PubMed
4.
Streissguth AP, Barr HM, Martin DC, Herman CS. Effects of maternal alcohol nicotine, and caffeine use during pregnancy on infant mental and motor development at eight months. Alc Clin Exp Res 1980;4(2):152–64.CrossRef
5.
Kramer MS. The etiology and prevention of low birthweight: Current knowledge and priorities for future research. In: Berendes H, Kessel S Yaffe S, (Eds.) Advances in the prevention of low birthweight. An international symposium. Washington, DC: National Center for Education in Maternal and Child Health, 1991.
6.
Lassen K, Oei TPS. Effects of maternal cigarette smoking during pregnancy on long-term physical and cognitive parameters of child development. Addict Behav 23:635–53.
7.
Law KL, Stroud LR, LaGasse LL, Niaura R. Smoking during pregnancy and newborn neurobehavior. Pediatrics 2003;111(6):1318–23.CrossRefPubMed
8.
Kandall SR, Albin S, Gartner LM, Lee KS, Eldelman A, Lowinson J. The narcotic-dependent mother: Fetal and neonatal consequences. Early Hum Dev 1977;1(2):159–69.CrossRefPubMed
9.
Finnegan LP, Kaltenbach KA. Neonatal abstinence syndrome. In: Hoekelman RA, Nelson NM, Seidel HM, (Eds.) Primary Pediatric Care, 2nd Ed. St. Louis: Mosby, 1992: 1367–78.
10.
Rangel C. The crack cocaine crisis (Joint hearings of Select Committee on Narcotics Abuse and control and select committee on children youth and families). Washington, DC, U.S. House of Representatives, 1986.
11.
Lester BM, LaGasse LL, Seifer R. Cocaine exposure and children: The meaning of subtle effects. Science 1998;282:633–4.CrossRefPubMed
12.
Delaney-Black V, Covington C, Templin T, Ager J. Prenatal cocaine exposure and child behavior. Pediatrics 1998;102:945–50.CrossRefPubMed
13.
Leech S, Richardson GA, Goldschmidt L, Day NL. Prenatal substance exposure: Effects on attention and impulsivity of 6-year olds. Neurotoxicol Teratol 1999;21(2):109–18.CrossRefPubMed
14.
Richardson GA, Conroy ML, Day NL. Prenatal cocaine exposure effects on the development of school-age children. Neurotoxicol Terat 1996;18(6):627–34.CrossRef
15.
Messinger DS, Bauer CR, Abhik D, Seifer R, Lester BM, Lagasse LL, Wright LL, Shankaran S, Bada HS, Smergilio VL, Langer JC, Beeghly M, Poole WK. The maternal lifestyle study: cognitive motor and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 113:1677–85.
16.
Lester BM. Vulnerable Infants Program of Rhode Island. Program funded by the Robert Wood Johnson Local Initiative Funding Partners Program and the Abandoned Infant Assistance Project, 2000.
17.
Smeriglio VL, Wilcox HC. Prenatal drug exposure and child outcome: Past, present, future. In: Lester BM, (Eds.) Clinics in perinatology: Prenatal drug exposure and child outcome. Philadelphia, PA: WB Saunders, 1999:1–16.
18.
Lukas SE. Proceedings of the National Consensus Meeting on the use, abuse, and sequelae of methamphetamine with implications for prevention, treatment, and research. Washington, DC: Center for Substance Abuse Treatment, 1997.
19.
U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, National Survey on Drug Use and Health, 2002 and 2003.
20.
U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Summary of findings from the 1999 National Household Survey on Drug Abuse (DHHS Publiciation No SMA00-3466, NHSDA Series H12, Rockville, MD.
21.
U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, National Survey on Drug Use and Health, 2002 and 2003.
22.
U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, DASIS Report: Primary Methamphetamine/Amphetamine Treatment Admissions 1992–2002, September 17, 2004.
23.
Miller MA. History and epidemiology of amphetamine abuse in the United States. In: Klee H, (Ed.) Amphetamine misuse: International perspectives on current trends. Amsterdam: Harwood Academic, 1997:113.
24.
Zhang Z. Drug and Alcohol Use and Related Matters among Arrestees. ADAM Program 2003, National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.
25.
Acuff-Smith KD, George M, Lorens SA, Vorhees CV. Preliminary evidence for methamphetamine-induced behavioral and ocular effects in rat offspring following exposure during early organogenesis. Psychopharmacology 1992;109(3):255–63.CrossRefPubMed
26.
Yamamoto Y, Yamanoto K, Fukui Y, Kurishita A. Teratogenic effects of methamphetamine in mice. Jpn J Legal Med 1992;46(2):126– 31.
27.
Cho DH, Lyu HM, Lee HB, Kim PY, Chin K. Behavioral teratogenicity of methamphetamine. J Toxicol Sci Suppl 1991;1:37–49.
28.
Cabrera TM, Levy AD, Li Q, van de Kar LD, Battaglia G. Prenatal methamphetamine attenuates serotonin mediated renin secretion in male and female rat progeny: Evidence for selective long-term dysfunction of serotonin pathways in brain. Synapse 1993;15(3):198–08.CrossRefPubMed
29.
Weissman AD, Caldecott-Hazard S. Developmental neurotoxicity to methamphetamines. Clin Exp Pharmacol Physiol 1995;22(5):372–4.PubMedCrossRef
30.
Eriksson M, Larsson G, Winbladh B, Zetterstrom R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand 1978;67:95–9.PubMedCrossRef
31.
Eriksson M, Larsson G, Zetterstrom R. Amphetamine addiction and pregnancy. II. Pregnancy, delivery, and the neonatal period. Socio-medical aspects. Acta Obstet Gynecol Scand 1981;60:253–9.PubMedCrossRef
32.
Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatr 1989;115:770–8.PubMedCrossRef
33.
Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. J Pediatr 1987;111:571–8.PubMedCrossRef
34.
Little BB, Snell LM, Gilstrap LC. Methamphetamine abuse during pregnancy: Outcome and fetal effects. Obstet Gynecol 1988;72:541–4.PubMed
35.
Struthers JM, Hansen RL. Visual recognition memory in drug-exposed infants. J Dev Behav Pediatr 1992;13:108–11.PubMedCrossRef
36.
Billing L, Eriksson M, Larsson G, Zetterstrom R. Amphetamine addiction and pregnancy. III. One year follow-up of the children. Psychosocial and pediatric aspects. Acta Paediatr Scand 1980;69:675–80.PubMedCrossRef
37.
Billing L, Eriksson M, Steneroth G, Zetterstrom R. Pre-school children of amphetamine-addicted mothers. I. Somatic and psychomotor development. Acta Paediatr Scand 1985;74:179–84.PubMedCrossRef
38.
Billing L, Eriksson M, Steneroth G, Zetterstrom R. Predictive indicators for adjustment in 4-year-old children whose mothers used amphetamine during pregnancy. Child Abus Negl 1988;12:503–7.CrossRef
39.
Billing L, Eriksson M, Jonsson B, Steneroth G. The influence of environmental factors on behavioral problems in 8-year-old children exposed to amphetamine during fetal life. Child Abus Negl 1994;18:3–9.CrossRef
40.
Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr 1996;85:204–8.PubMedCrossRef
41.
Catanzarite VA, Stein DA. ‘Crystal’ and pregnancy—Methamphetamine-associated maternal deaths. West J Med 1995;162:454–8.PubMed
42.
Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998;25(1):119–38.CrossRefPubMed
43.
U.S. Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse. National Pregnancy and Health Survey: Drug Use among Women Delivering Live Births: 1992. NIH Publication No. 96–3819, 1996.
44.
Derauf C, Katz AR, Frank DA, Grandinetti A, Easa D. The prevalence of methamphetamine and other drug use during pregnancy in Hawaii. J Drug Issues 2003;2–16.
45.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Smoking during pregnancy—United States, 1990–2002. MMWR 2004;53:911–17.
46.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Surveillance Summaries, Surveillance for disparities in maternal health-related behaviors—selected states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000-2001. MMWR 2004 53 SS4 1–14.
47.
Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003;101(2):374–9.CrossRefPubMed
48.
Leonardson GR, Loudenberg R. Risk factors for alcohol use during pregnancy in a multistate study. Neroutoxicol Teratol 2003;25(6):651–8.CrossRef
49.
Fuani EF, White J, Lee MJ, Allen M, Kuczynski E. Compliance with prenatal care visits in substance abusers. J Mat Fetal Neonatal Med 2003;14(5):329–32.CrossRef
50.
Bauer CR, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, Smeriglio VL, Finnegan LP, Maza PL, Verter J. The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol 2002;186(3):487–95.CrossRefPubMed
51.
Lester BM, Tronick EZ, LaGasse L, Seifer R, Bauer CR, Shankaran S, Bada HS, Wright LL, Smeriglio VL, Lu J, Finnegan LP, Maza PL. The maternal lifestyle study: Effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics 2002;110(6):1182–92.CrossRefPubMed
52.
Hollingshead AB. Four factor index of social status. Department of Sociology: Yale University, New Haven, CT, 1975.
53.
El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylanck L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol 2003;23(5):354–60.CrossRefPubMed
54.
Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Rieber C, Vandersloot D, Zweben J, and the Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004;99:708–17.CrossRefPubMed
55.
Finkelstein N. Treatment programming for alcohol and drug-dependent pregnant women. Special Issue: Maternal Drug Use: Issues and Implications for Mother and Child. Inter J Addict 1993;28(13):1275–309.
56.
Svikis DS, Haug N, Lee J, Timpson R. Predictors of treatment participation and retention in an intensive outpatient program for pregnant drug abusing women. In: Harris LS, (Ed.), National Institute of Drug Abuse Research Monograph Series 163. Rockville, MD: National Institute on Drug Abuse, 1996:351.
Metadata
Title
Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study
Authors
Amelia M. Arria, PhD
Chris Derauf, MD
Linda L. LaGasse, PhD
Penny Grant, MD
Rizwan Shah, MD
Lynne Smith, MD
William Haning, MD
Marilyn Huestis, PhD
Arthur Strauss, MD
Sheri Della Grotta, MPH
Jing Liu, PhD
Barry Lester, PhD
Publication date
01-05-2006
Publisher
Springer US
Published in
Maternal and Child Health Journal / Issue 3/2006
Print ISSN: 1092-7875
Electronic ISSN: 1573-6628
DOI
https://doi.org/10.1007/s10995-005-0052-0

Other articles of this Issue 3/2006

Maternal and Child Health Journal 3/2006 Go to the issue

Report

Identifying Multiple Gestation Groups Using State-Level Birth and Fetal Death Certificate Data

BriefCommunication

What Fathers Need: A Countywide Assessment of the Needs of Fathers of Young Children

Original Paper

Early Postnatal Care Among Healthy Newborns in 19 States: Pregnancy Risk Assessment Monitoring System, 2000

Original Article

A Positive Orientation Toward Early Motherhood Is Associated with Unintended Pregnancy Among New Orleans Youth

OriginalPaper

Policies and Practices Related to Breastfeeding in Massachusetts: Hospital Implementation of the Ten Steps to Successful Breastfeeding1

OriginalPaper

Teen Maternal Age and Very Preterm Birth of Twins